Status:
COMPLETED
Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Nephrotic Syndrome
Hyperlipidemia
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The purpose of this research study is to learn if using statin in patients with nephrotic syndrome could lower the risk of blood clots. Nephrotic syndrome is a collection of signs and symptoms that oc...
Detailed Description
Venous thromboembolic (VTE) events are common in the nephrotic syndrome (NS) occurring in up to 30% of patients when systematically screened. The investigator proposes to explore a novel mechanism for...
Eligibility Criteria
Inclusion
- • Prevalent or incident patients of either sex, ages 18-70, with Membranous Nephropathy (MN) , Focal Segmental GlomeruloSclerosis (FSGS), or Minimal Change Disease (MCD).
- Proteinuria ≥ 3.0 g/day by 24hr urine collection or urine protein/creatinine ratio ≥ 2.
- Hyperlipidemia as defined by fasting or direct LDL ≥ 150 mg/dl. -
Exclusion
- Inability or unwillingness to comply with the study protocol and follow-up visits.
- Patients unable to provide written consent will be excluded.
- \-
Key Trial Info
Start Date :
May 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2017
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT01845428
Start Date
May 1 2012
End Date
January 1 2017
Last Update
August 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Unc Kidney Center
Chapel Hill, North Carolina, United States, 27599-7155